Get the Stockscreener App
3.28
3.81%
-0.13
Lixte Biotechnology Holdings Inc stock is traded at $3.28, with a volume of 79,757.
It is down -3.81% in the last 24 hours and down -19.41% over the past month.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$3.41
Open:
$3.1797
24h Volume:
79,757
Relative Volume:
0.94
Market Cap:
$28.29M
Revenue:
-
Net Income/Loss:
$-4.69M
P/E Ratio:
-1.4077
EPS:
-2.33
Net Cash Flow:
$-3.81M
1W Performance:
+7.89%
1M Performance:
-19.41%
6M Performance:
-20.19%
1Y Performance:
+38.40%
1-Day Range:
$3.1713
$3.40
1-Week Range:
$2.86
$3.525
52-Week Range:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
433 PLAZA REAL, BOCA RATON
Compare LIXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.2501 | 29.68M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.51 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.61 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.92 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
Retail Trends: Is Lixte Biotechnology Holdings Inc a stock for growth or value investors2025 Analyst Calls & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy - NewMediaWire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy - Digital Journal
Datavault AI (NASDAQ: DVLT) Closes Acquisition of API Media Innovation - financial-news.co.uk
De La Soul Set to Lead Good Health Summit at Morehouse College - EBONY Magazine
Stop Loss: Can C3is Inc weather a recessionEarnings Overview Summary & Safe Capital Growth Plans - baoquankhu1.vn
LIXTE Biotechnology Advances Novel Cancer Therapy Approach Targeting PP2A Enzyme - citybuzz -
Spartan Capital Securities, LLC Proudly Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering - Big News Network.com
Highs Report: What makes Lixte Biotechnology Holdings Inc Equity Warrant stock attractive today2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Is Lixte Biotechnology Holdings Inc stock a value trapFed Meeting & AI Forecasted Entry and Exit Points - baoquankhu1.vn
LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit - Yahoo Finance
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit - Digital Journal
LIXTE Biotechnology Sponsors Health Equity Summit at Morehouse College, Linking Cancer Research to Community Wellness - citybuzz -
De La Soul's 'Good Health' summit targets Black men's wellness - Stock Titan
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE - The Globe and Mail
Lixte Biotechnology to Present at DealFlow Discovery Conference as Clinical Trials Advance - citybuzz -
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 - manilatimes.net
How Lixte Biotechnology Holdings Inc. stock compares to growth peersSector Performance Review & Rapid Portfolio Trading - bollywoodhelpline.com
Is Lixte Biotechnology Holdings Inc. a stock for growth or value investorsQuarterly Earnings Summary & Real-Time Volume Trigger Notifications - bollywoodhelpline.com
Breakout Move: Can Arvinas Inc grow without external fundingJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Aug Movers: Is OPAD a play on infrastructure spending2025 Trade Ideas & Expert Approved Trade Ideas - baoquankhu1.vn
Pullback Watch: Whats the profit margin of Lixte Biotechnology Holdings IncJuly 2025 Action & Growth Oriented Trading Recommendations - baoquankhu1.vn
Institution Moves: How Lixte Biotechnology Holdings Inc stock performs after earningsJuly 2025 Market Mood & Low Volatility Stock Suggestions - Bộ Nội Vụ
LIXTE Biotechnology Engages IBN to Amplify Communications for Cancer Therapy Development - citybuzz -
About Us - FinancialContent
LIXTE Biotechnology (LIXT) Enhances Visibility with New Communications Strategy - GuruFocus
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc. - The Manila Times
Breakout Zone: Can Lixte Biotechnology Holdings Inc Equity Warrant withstand a market correctionPortfolio Gains Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Weekly Trades: How Lixte Biotechnology Holdings Inc stock compares to growth peersEarnings Performance Report & Real-Time Buy Signal Notifications - Bộ Nội Vụ
Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuationTreasury Yields & Expert-Curated Trade Recommendations - ulpravda.ru
Will Lixte Biotechnology Holdings Inc. stock see insider buyingTake Profit & Smart Swing Trading Techniques - Улправда
Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesPortfolio Return Summary & Entry and Exit Point Strategies - ulpravda.ru
Should I hold or sell Lixte Biotechnology Holdings Inc. stock in 2025Weekly Investment Summary & Accurate Technical Buy Alerts - Улправда
Can Lixte Biotechnology Holdings Inc. (8640) stock ride next bull market cycleQuarterly Market Review & Technical Buy Zone Confirmation - Улправда
LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - NewMediaWire
Will Lixte Biotechnology Holdings Inc. (8640) stock beat revenue estimatesFed Meeting & Low Risk Entry Point Tips - Улправда
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Lixte Biotechnology Expands Ovarian Cancer Trial with MD Anderson and GSK - citybuzz -
Will Lixte Biotechnology Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & AI Driven Stock Reports - ulpravda.ru
Lixte Biotechnology files to sell 5.26M shares of common stock, warrants - MSN
How strong is Lixte Biotechnology Holdings Inc. Equity Warrant stock revenue growth2025 Trade Ideas & Entry Point Strategy Guides - Улправда
Lixte Biotechnology announces new registered direct offering - MSN
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - financial-news.co.uk
Breakout Zone: Why Lixte Biotechnology Holdings Inc. stock is a value investor pickJuly 2025 Weekly Recap & Real-Time Market Sentiment Reports - Улправда
Can Lixte Biotechnology Holdings Inc. stock continue upward trendEarnings Forecast Updates & High Yield Trading Growth - ulpravda.ru
Lixte Biotechnology Holdings (NASDAQ: LIXT) Announces $4.3M Registered Direct Offering Priced at Market - Digital Journal
LIXTE Biotechnology Advances Novel Cancer Treatment Platform Through Clinical Trials and Strategic Moves - citybuzz -
Lixte Biotechnology Holdings Secures $4.3 Million in Registered Direct Offering to Advance Cancer Drug Development - citybuzz -
About Us | Oil & Gas JournalLIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’ - FinancialContent
Pasadena Star News - FinancialContent
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):